Clarithromycin/clofazimine/rifabutin companion diagnostic - RedHill Biopharma/Quest Diagnostics
Alternative Names: RHB 104 companion diagnosticLatest Information Update: 06 Oct 2020
Price :
$50 *
At a glance
- Originator RedHill Biopharma
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Crohn's disease
- Phase II Multiple sclerosis
Most Recent Events
- 06 Oct 2020 Phase III development in Crohn's disease (Diagnosis) is still ongoing in USA, Canada, New Zealand, Australia, Bulgaria, Czech Republic, Poland, Serbia, Slovakia and Israel (NCT01951326)
- 05 Sep 2017 Phase-III development is ongoing in USA, Canada, New Zealand, Australia, Bulgaria, Czech Republic, Poland, Serbia, Slovakia and Israel (NCT01951326)
- 06 Oct 2016 RedHill Biopharma collaborates with Baylor College of Medicine to develop companion diagnostic for the fixed dose combination of clarithromycin/clofazimine/rifabutin